{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:15:41Z","timestamp":1790846141064,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycythemia vera (PV) and essential thrombocythemia (ET) are both driven by JAK-STAT pathway activation and consequently much of the recent research efforts to improve the management and outcomes of patients with these neoplasms have centered around inhibition of this pathway. In addition to newer JAK inhibitors and improved interferons, promising novel agents exploiting a growing understanding of PV and ET pathogenesis and disease evolution mechanisms are being developed. These agents may modify the disease course in addition to cytoreduction. Histone deacetylase, MDM2 and telomerase inhibitors in patients with PV\/ET have demonstrated clinically efficacy and serve as chief examples. Hepcidin mimetics, limiting iron availability to red blood cell precursors, offer an exciting alternative to therapeutic phlebotomy and have the potential to revolutionize management for patients with PV. Many of these newer agents are found to improve hematologic parameters and symptom burden, but their role in thrombotic risk reduction and disease progression control is currently unknown. The results of larger, randomized studies to confirm the early efficacy signals observed in phase 1\/2 trials are eagerly awaited.<\/jats:p>","DOI":"10.1186\/s40364-021-00298-5","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T07:05:06Z","timestamp":1622185506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging agents and regimens for polycythemia vera and essential thrombocythemia"],"prefix":"10.1186","volume":"9","author":[{"given":"Rory M.","family":"Shallis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-778X","authenticated-orcid":false,"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"298_CR1","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","volume":"42","author":"RM Shallis","year":"2020","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev. 2020;42:100706. https:\/\/doi.org\/10.1016\/j.blre.2020.100706.","journal-title":"Blood Rev"},{"issue":"8","key":"298_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Vannucchi AM. Genetic risk assessment in myeloproliferative neoplasms. Mayo Clin Proc. 2017;92(8):1283\u201390. https:\/\/doi.org\/10.1016\/j.mayocp.2017.06.002.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"298_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379. https:\/\/doi.org\/10.1182\/blood-2016-10-695940.","journal-title":"Blood."},{"issue":"33","key":"298_CR4","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","volume":"33","author":"BL Stein","year":"2015","unstructured":"Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, et al. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol. 2015;33(33):3953\u201360. https:\/\/doi.org\/10.1200\/JCO.2015.61.6474.","journal-title":"J Clin Oncol"},{"issue":"9464","key":"298_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9.","journal-title":"Lancet."},{"issue":"6","key":"298_CR6","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162\u20138. https:\/\/doi.org\/10.1182\/blood-2005-03-1320.","journal-title":"Blood."},{"issue":"17","key":"298_CR7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390. https:\/\/doi.org\/10.1056\/NEJMoa051113.","journal-title":"N Engl J Med"},{"issue":"9","key":"298_CR8","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","volume":"107","author":"F Passamonti","year":"2006","unstructured":"Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676\u201382. https:\/\/doi.org\/10.1182\/blood-2005-09-3826.","journal-title":"Blood."},{"issue":"10","key":"298_CR9","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472\u20136. https:\/\/doi.org\/10.1182\/blood-2006-04-018879.","journal-title":"Blood."},{"issue":"7","key":"298_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. https:\/\/doi.org\/10.1371\/journal.pmed.0030270.","journal-title":"PLoS Med"},{"issue":"25","key":"298_CR11","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1311347.","journal-title":"N Engl J Med"},{"issue":"25","key":"298_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa1312542.","journal-title":"N Engl J Med"},{"issue":"20","key":"298_CR13","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1182\/blood-2016-05-643346","volume":"128","author":"E Rumi","year":"2016","unstructured":"Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood. 2016;128(20):2403\u201314. https:\/\/doi.org\/10.1182\/blood-2016-05-643346.","journal-title":"Blood."},{"issue":"1","key":"298_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3324\/haematol.2013.101279","volume":"99","author":"KI Mills","year":"2014","unstructured":"Mills KI, McMullin MF. Mutational spectrum defines primary and secondary myelofibrosis. Haematologica. 2014;99(1):2\u20133. https:\/\/doi.org\/10.3324\/haematol.2013.101279.","journal-title":"Haematologica."},{"issue":"7","key":"298_CR15","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","volume":"92","author":"M Yogarajah","year":"2017","unstructured":"Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017;92(7):1118\u201328. https:\/\/doi.org\/10.1016\/j.mayocp.2017.05.010.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"298_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317\u201325. https:\/\/doi.org\/10.7326\/M17-0028.","journal-title":"Ann Intern Med"},{"issue":"10","key":"298_CR17","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","volume":"32","author":"AR Landtblom","year":"2018","unstructured":"Landtblom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Bjorkholm M, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203\u201310. https:\/\/doi.org\/10.1038\/s41375-018-0027-y.","journal-title":"Leukemia."},{"issue":"1","key":"298_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/asheducation-2015.1.340","volume":"2015","author":"D Radia","year":"2015","unstructured":"Radia D, Geyer HL. Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematol Am Soc Hematol Educ Program. 2015;2015(1):340\u20138. https:\/\/doi.org\/10.1182\/asheducation-2015.1.340.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"298_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1586\/ehm.12.69","volume":"6","author":"RT Silver","year":"2013","unstructured":"Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49\u201358. https:\/\/doi.org\/10.1586\/ehm.12.69.","journal-title":"Expert Rev Hematol"},{"key":"298_CR20","doi-asserted-by":"publisher","unstructured":"Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. 2020. https:\/\/doi.org\/10.1038\/s41375-020-01020-4.","DOI":"10.1038\/s41375-020-01020-4"},{"issue":"Supplement 1","key":"298_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141223","volume":"136","author":"R Daltro De Oliveira","year":"2020","unstructured":"Daltro De Oliveira R, Soret-Dulphy J, Zhao L-P, Marcault C, Gauthier N, Verger E, et al. Interferon-Alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136(Supplement 1):35\u20136.","journal-title":"Blood"},{"issue":"10","key":"298_CR22","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","volume":"117","author":"F Passamonti","year":"2011","unstructured":"Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813\u20136. https:\/\/doi.org\/10.1182\/blood-2010-11-316810.","journal-title":"Blood."},{"issue":"5","key":"298_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459\u201368. https:\/\/doi.org\/10.1056\/NEJMoa065202.","journal-title":"N Engl J Med"},{"issue":"3","key":"298_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316\u201331. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0736.","journal-title":"Cancer Discov"},{"issue":"5","key":"298_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","volume":"30","author":"S Koschmieder","year":"2016","unstructured":"Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30(5):1018\u201324. https:\/\/doi.org\/10.1038\/leu.2016.12.","journal-title":"Leukemia."},{"issue":"12","key":"298_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1002028.","journal-title":"N Engl J Med"},{"issue":"5","key":"298_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1409002.","journal-title":"N Engl J Med"},{"issue":"7","key":"298_CR28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821\u20139. https:\/\/doi.org\/10.3324\/haematol.2016.143644.","journal-title":"Haematologica."},{"issue":"2","key":"298_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","volume":"4","author":"A Masciulli","year":"2020","unstructured":"Masciulli A, Ferrari A, Carobbio A, Ghirardi A, Barbui T. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2020;4(2):380\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2019001158.","journal-title":"Blood Adv"},{"issue":"1","key":"298_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(16)30558-7.","journal-title":"Lancet Oncol"},{"key":"298_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2017.08.010","volume":"61","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, et al. A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leuk Res. 2017;61:89\u201395. https:\/\/doi.org\/10.1016\/j.leukres.2017.08.010.","journal-title":"Leuk Res"},{"key":"298_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.leukres.2018.06.014","volume":"71","author":"J Berdeja","year":"2018","unstructured":"Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, et al. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. Leuk Res. 2018;71:82\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2018.06.014.","journal-title":"Leuk Res"},{"issue":"9","key":"298_CR33","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","volume":"105","author":"AL Sorensen","year":"2020","unstructured":"Sorensen AL, Mikkelsen SU, Knudsen TA, Bjorn ME, Andersen CL, Bjerrum OW, et al. Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. 2020;105(9):2262\u201372. https:\/\/doi.org\/10.3324\/haematol.2019.235648.","journal-title":"Haematologica."},{"issue":"3","key":"298_CR34","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4.","journal-title":"Lancet Haematol"},{"issue":"8","key":"298_CR35","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","volume":"34","author":"A Rambaldi","year":"2020","unstructured":"Rambaldi A, Iurlo A, Vannucchi AM, Noble R, von Bubnoff N, Guarini A, et al. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib\/II study. Leukemia. 2020;34(8):2234\u20137. https:\/\/doi.org\/10.1038\/s41375-020-0735-y.","journal-title":"Leukemia."},{"issue":"Supplement 1","key":"298_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-135868","volume":"136","author":"J Mascarenhas","year":"2020","unstructured":"Mascarenhas J, Higgins B, Anders D, Burbury K, El-Galaly TC, Gerds AT, et al. Safety and efficacy of idasanutlin in patients (pts) with hydroxyurea (HU)-resistant\/intolerant polycythemia vera (PV): results of an international Phase II study. Blood. 2020;136(Supplement 1):29\u201331.","journal-title":"Blood"},{"issue":"Supplement 1","key":"298_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-137304","volume":"136","author":"Y Ginzburg","year":"2020","unstructured":"Ginzburg Y, Kremyanskaya M, Kuykendall AT, Yacoub A, Yang J, Gupta SK, et al. Hepcidin mimetic (PTG-300) reverses iron deficiency while controlling hematocrit in polycythemia vera patients. Blood. 2020;136(Supplement 1):40\u20131.","journal-title":"Blood"},{"issue":"15","key":"298_CR38","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","volume":"130","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017;130(15):1768\u201371. https:\/\/doi.org\/10.1182\/blood-2017-02-765032.","journal-title":"Blood."},{"issue":"17","key":"298_CR39","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","volume":"130","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130(17):1889\u201397. https:\/\/doi.org\/10.1182\/blood-2017-05-785790.","journal-title":"Blood."},{"issue":"10","key":"298_CR40","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1056\/NEJMoa1503479","volume":"373","author":"GM Baerlocher","year":"2015","unstructured":"Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, et al. Telomerase inhibitor Imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373(10):920\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1503479.","journal-title":"N Engl J Med"},{"issue":"15","key":"298_CR41","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762\u20139. https:\/\/doi.org\/10.1182\/blood-2015-04-637280.","journal-title":"Blood."},{"key":"298_CR42","doi-asserted-by":"crossref","unstructured":"Illes A, Pinczes LI, Egyed M. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera. Expert Opin Drug Metab Toxicol. 2021;17(1):3\u20137.","DOI":"10.1080\/17425255.2021.1839050"},{"issue":"Supplement 1","key":"298_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2020-136973","volume":"136","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Long-term use of ropeginterferon Alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension. Blood. 2020;136(Supplement 1):33.","journal-title":"Blood"},{"issue":"1","key":"298_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1868-7083-4-5","volume":"4","author":"GP Delcuve","year":"2012","unstructured":"Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012;4(1):5. https:\/\/doi.org\/10.1186\/1868-7083-4-5.","journal-title":"Clin Epigenetics"},{"issue":"12","key":"298_CR45","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/13543784.2016.1250882","volume":"25","author":"P Bose","year":"2016","unstructured":"Bose P, Verstovsek S. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016;25(12):1393\u2013403. https:\/\/doi.org\/10.1080\/13543784.2016.1250882.","journal-title":"Expert Opin Investig Drugs"},{"issue":"16","key":"298_CR46","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1182\/blood-2011-02-336743","volume":"119","author":"H Akada","year":"2012","unstructured":"Akada H, Akada S, Gajra A, Bair A, Graziano S, Hutchison RE, et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood. 2012;119(16):3779\u201389. https:\/\/doi.org\/10.1182\/blood-2011-02-336743.","journal-title":"Blood."},{"issue":"24","key":"298_CR47","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","volume":"114","author":"Y Wang","year":"2009","unstructured":"Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009;114(24):5024\u201333. https:\/\/doi.org\/10.1182\/blood-2009-05-222133.","journal-title":"Blood."},{"issue":"4","key":"298_CR48","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.leu.2405049","volume":"22","author":"V Guerini","year":"2008","unstructured":"Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008;22(4):740\u20137. https:\/\/doi.org\/10.1038\/sj.leu.2405049.","journal-title":"Leukemia."},{"issue":"5","key":"298_CR49","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1182\/blood-2006-03-014126","volume":"108","author":"S Carta","year":"2006","unstructured":"Carta S, Tassi S, Semino C, Fossati G, Mascagni P, Dinarello CA, et al. Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood. 2006;108(5):1618\u201326. https:\/\/doi.org\/10.1182\/blood-2006-03-014126.","journal-title":"Blood."},{"issue":"9","key":"298_CR50","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/sj.leu.2404860","volume":"21","author":"J Golay","year":"2007","unstructured":"Golay J, Cuppini L, Leoni F, Mico C, Barbui V, Domenghini M, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21(9):1892\u2013900. https:\/\/doi.org\/10.1038\/sj.leu.2404860.","journal-title":"Leukemia."},{"issue":"4","key":"298_CR51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","volume":"150","author":"A Rambaldi","year":"2010","unstructured":"Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446\u201355.","journal-title":"Br J Haematol"},{"issue":"5","key":"298_CR52","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.12332","volume":"161","author":"G Finazzi","year":"2013","unstructured":"Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013;161(5):688\u201394. https:\/\/doi.org\/10.1111\/bjh.12332.","journal-title":"Br J Haematol"},{"issue":"6","key":"298_CR53","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","volume":"29","author":"HT Chifotides","year":"2020","unstructured":"Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020;29(6):525\u201336. https:\/\/doi.org\/10.1080\/13543784.2020.1761323.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"298_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000054","volume":"2","author":"JS Jutzi","year":"2018","unstructured":"Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J, et al. LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone. Hemasphere. 2018;2(3):e54. https:\/\/doi.org\/10.1097\/HS9.0000000000000054.","journal-title":"Hemasphere."},{"issue":"17","key":"298_CR55","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","volume":"14","author":"S Shangary","year":"2008","unstructured":"Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14(17):5318\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5136.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"298_CR56","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","volume":"120","author":"M Lu","year":"2012","unstructured":"Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120(15):3098\u2013105. https:\/\/doi.org\/10.1182\/blood-2012-02-410712.","journal-title":"Blood."},{"issue":"10","key":"298_CR57","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/onc.2011.313","volume":"31","author":"M Nakatake","year":"2012","unstructured":"Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31(10):1323\u201333. https:\/\/doi.org\/10.1038\/onc.2011.313.","journal-title":"Oncogene."},{"issue":"6","key":"298_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood.2018893545","volume":"134","author":"J Mascarenhas","year":"2019","unstructured":"Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134(6):525\u201333. https:\/\/doi.org\/10.1182\/blood.2018893545.","journal-title":"Blood."},{"issue":"22","key":"298_CR59","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1182\/bloodadvances.2020002379","volume":"4","author":"BK Marcellino","year":"2020","unstructured":"Marcellino BK, Farnoud N, Cassinat B, Lu M, Verger E, McGovern E, et al. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Adv. 2020;4(22):5735\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2020002379.","journal-title":"Blood Adv."},{"issue":"11","key":"298_CR60","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1038\/leu.2017.78","volume":"31","author":"G Mosoyan","year":"2017","unstructured":"Mosoyan G, Kraus T, Ye F, Eng K, Crispino JD, Hoffman R, et al. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Leukemia. 2017;31(11):2458\u201367. https:\/\/doi.org\/10.1038\/leu.2017.78.","journal-title":"Leukemia."},{"issue":"22","key":"298_CR61","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/bloodadvances.2019000167","volume":"3","author":"GM Baerlocher","year":"2019","unstructured":"Baerlocher GM, Haubitz M, Braschler TR, Brunold C, Burington B, Oppliger Leibundgut E, et al. Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia. Blood Adv. 2019;3(22):3724\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2019000167.","journal-title":"Blood Adv."},{"issue":"1","key":"298_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500.","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"298_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000243791","volume":"122","author":"E Nemeth","year":"2009","unstructured":"Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122(2\u20133):78\u201386. https:\/\/doi.org\/10.1159\/000243791.","journal-title":"Acta Haematol"},{"issue":"10","key":"298_CR64","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105\u201316. https:\/\/doi.org\/10.1038\/s41375-018-0207-9.","journal-title":"Leukemia."}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-021-00298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-021-00298-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-021-00298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T07:31:46Z","timestamp":1699083106000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-021-00298-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1186\/s40364-021-00298-5","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.A.P. consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squib, CTI BioPharma and PharmaEssentia. N.A.P. received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, Kartos Therapeutics. None of these relationships were related to the development of this manuscript. All other authors report no relevant disclosures\/competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}